Research Article
Mupirocin-Resistant Staphylococcus aureus in Iran: A Biofilm Production and Genetic Characteristics
Table 1
Distribution of resistance among HO and CO HLMUPR MRSA isolated from clinical samples.
| | Antibiotic | Mupirocin-resistant S. aureus (%) | Total (%) | | Hospital onset | Community onset |
| | Penicillin | 30 (62.5) | 18 (37.5) | 48 (100) | | Gentamicin | 24 (60) | 16 (40) | 40 (83.3) | | Kanamycin | 13 (61.9) | 8 (38.1) | 21 (43.8) | | Amikacin | 14 (70) | 6 (30) | 20 (41.7) | | Tobramycin | 8 (53.3) | 7 (46.7) | 15 (31.3) | | Tetracycline | 19 (59.4) | 13 (40.6) | 32 (66.7) | | Erythromycin | 22 (64.7) | 12 (35.3) | 34 (70.8) | | Clindamycin | 13 (65) | 7 (35) | 20 (41.7) | | Ciprofloxacin | 22 (59.5) | 15 (40.5) | 37 (77.1) | | Rifampin | 7 (63.6) | 4 (36.4) | 11 (22.9) | | Trimethoprim-sulfamethoxazole | 9 (64.3) | 5 (35.7) | 14 (29.2) | | Quinupristin-dalfopristin | 7 (63.6) | 4 (36.4) | 11 (22.9) | | Fusidic acid | 4 (100) | 0 (0) | 4 (8.3) |
|
|
